FINWIRES · TerminalLIVE
FINWIRES

HKG:2616

9 stories mentioning HKG:2616Updated just now

Every FINWIRES story that references HKG:2616, newest first.

What's the latest news on HKG:2616?

Asia

CStone Pharma CEO Buys HK$2.7 Million of Shares

CStone Pharmaceuticals (HKG:2616) said CEO, President of R&D and executive director Jianxin Yang bought 496,000 shares in the open market for more than HK$2.7 million from Sept. 17 to 22, according to a Thursday Hong Kong bourse filing.Following the purchases, Yang's interest in CStone rose to about 5.31% of the company's issued share capital. He has bought a total of 14.21 million shares in the open market since becoming CEO in August 2022.

HKG:2616
Asia

CStone Pharmaceuticals Joins Stock Connect Southbound Trading

CStone Pharmaceuticals (HKG:2616) said its Hong Kong-listed shares have been added to the eligible securities list for southbound trading under Stock Connect, effective Sept. 7, according to a same-day Hong Kong bourse filing.Shares of the biopharmaceutical company fell nearly 1% in recent trade.

HKG:2616
Asia

CStone Pharmaceuticals' Application for Tumor Drug Gets China Nod in 23 Days

CStone Pharmaceuticals' (HKG:2616) investigational new drug application for CS5007 was rapidly approved by China's National Medical Products Administration in 23 days.The global multicenter phase I study of the tumor drug began in Australia in June, with the first patient successfully enrolled, and will be conducted in parallel in China, according to a Friday Hong Kong bourse filing.

HKG:2616
Asia

CStone Pharma Taps Arrotex to Commercialize Sugemalimab in Australia, New Zealand

CStone Pharmaceuticals (HKG:2616) signed an exclusive commercialization agreement with Australia's Arrotex Pharmaceuticals for its cancer immunotherapy sugemalimab in Australia and New Zealand, according to a Thursday Hong Kong bourse filing.The pharma company will receive an upfront payment, potential regulatory and commercial milestone payments, and a profit share on sales.Arrotex will hold exclusive commercialization rights for sugemalimab across all approved and future indications in the two markets, subject to regulatory approval, and will oversee regulatory filings and commercialization.

HKG:2616
Asia

CStone Pharmaceuticals Drug Receives Ethics Approval in Australia

CStone Pharmaceuticals (HKG:2616) received ethics approval to begin clinical trials of its core candidate CS5007 in Australia, according to a Friday filing with the Hong Kong bourse.The firm plans to enroll 310 patients in China and Australia to study the cancer treatment's effects.

HKG:2616
Asia

CStone Pharmaceuticals Plans Share Buyback

CStone Pharmaceuticals (HKG:2616) intends to buy back up to nearly 136.5 million shares from the open market from time to time under a mandate approved June 25, 2025, according to a Wednesday Hong Kong bourse filing.The repurchase plan is expected to be implemented following the American Society of Clinical Oncology (ASCO) Annual Meeting.

HKG:2616
Asia

CStone Pharmaceuticals Begins Commercial Distribution of Locally Manufactured Pralsetinib

CStone Pharmaceuticals (HKG:2616) began nationwide commercial supply of locally manufactured pralsetinib capsules in China, according to a Monday filing with the Hong Kong bourse.The oncology drugmaker said the first batch shipment marks the establishment of a localized supply chain for the therapy.CStone expects full-year 2026 sales revenue for pralsetinib capsules to exceed 300 million yuan, the filing said.

HKG:2616
Asia

CStone Pharmaceuticals Completes HK$1.05 Billion Share Offering

CStone Pharmaceuticals (HKG:2616) completed a share offering to raise about HK$1.05 billion in net proceeds, according to a Wednesday Hong Kong bourse filing.Shares of the company fell nearly 3% in late morning trade Thursday.The pharmaceutical firm placed 118 million new shares at HK$8.97 each to at least six independent investors.The placing shares represent about 7.40% of the company's enlarged issued share capital.Net proceeds will be used mainly for research and development of its oncology pipeline, with the remainder for general corporate purposes.

HKG:2616
Asia

CStone Pharmaceuticals Seeks HK$1 Billion via Share Placement

CStone Pharmaceuticals (HKG:2616) plans to raise about HK$1.05 billion in net proceeds through a share placement, according to a Wednesday Hong Kong bourse filing.The pharmaceutical firm agreed to place 118 million new shares at HK$8.97 each to at least six independent investors.The placing price represents a discount of about 7% to the last closing price and about 7.9% to the five-day average price, the filing said.The placing shares represent about 8% of the company's existing issued share capital.Net proceeds will be used mainly for research and development of its oncology pipeline, with the remainder for general corporate purposes.

HKG:2616

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2616 in your portfolio
WheelAI
WheelAI
Analyze HKG:2616 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2616